Successful use of empagliflozin to treat neutropenia in two <scp>G6PC3</scp> ‐deficient children: Impact of a mutation in <scp>SGLT5</scp>-Reference-Cited by-同舟云学术

Successful use of empagliflozin to treat neutropenia in two G6PC3 ‐deficient children: Impact of a mutation in SGLT5

Published:2022-05-24 Issue:4 Volume:45 Page:759-768
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:J of Inher Metab Disea

Author:

Boulanger Cécile¹^ORCID,Stephenne Xavier²^ORCID,Diederich Jennifer³,Mounkoro Pierre³,Chevalier Nathalie³,Ferster Alina⁴^ORCID,Van Schaftingen Emile³^ORCID,Veiga‐da‐Cunha Maria³^ORCID

Affiliation:

1. Biologie Hématologique Cliniques Universitaires Saint‐Luc, UCLouvain Brussels Belgium

2. Service de Gastro‐Entérologie et Hépatologie Pédiatrique Cliniques Universitaires Saint‐Luc, UCLouvain Brussels Belgium

3. Groupe de Recherches Metaboliques de Duve Institute, UCLouvain Brussels Belgium

4. Department of Hematology/Oncology Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles Brussels Belgium

Funder

Fonds De La Recherche Scientifique - FNRS

Cliniques Universitaires Saint-Luc

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jimd.12509

Reference22 articles.

1. A Syndrome with Congenital Neutropenia and Mutations inG6PC3

2. A Gene on Chromosome 11q23 Coding for a Putative Glucose- 6-Phosphate Translocase Is Mutated in Glycogen-Storage Disease Types Ib and Ic

3. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency

4. Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population

5. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and clinical characterization of a founder mutation causing G6PC3 deficiency;2024-07-11

2. Refractory wound healing and cytopenias treated with a sodium-glucose cotransporter-2 inhibitor in a patient with glucose-6-phosphatase catalytic subunit 3 deficiency;JAAD Case Reports;2024-07

3. Molecular and clinical characterization of a founder mutation causing G6PC3 deficiency;2024-05-14

4. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review;Pediatric Drugs;2024-04-18

5. Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects;Diabetes, Metabolic Syndrome and Obesity;2024-03